Originally published In Press as doi:10.1074/jbc.M100093200 on July 11, 2001
J. Biol. Chem., Vol. 276, Issue 36, 33986-33994, September 7, 2001
Cross-talk between the p42/p44 MAP Kinase and Smad
Pathways in Transforming Growth Factor
1-induced Furin Gene
Transactivation*
François
Blanchette
,
Nathalie
Rivard§,
Penny
Rudd
,
Francine
Grondin
,
Liliana
Attisano¶, and
Claire M.
Dubois
From the
Immunology Division and the
§ Department of Anatomy and Cell Biology, Faculty of
Medicine, Université de Sherbrooke, Sherbrooke, Quebec J1H 5N4,
Canada and the ¶ Department of Anatomy and Cell Biology,
University of Toronto, Toronto, Ontario M5S 1A8, Canada
Received for publication, January 4, 2001, and in revised form, June 26, 2001
 |
ABSTRACT |
Furin, a predominant
convertase of the cellular constitutive secretory pathway, is known to
be involved in the maturation of a number of growth/differentiation
factors, but the mechanisms governing its expression remain
elusive. We have previously demonstrated that transforming growth
factor (TGF)
1, through the activation of Smad transducers,
regulates its own converting enzyme, furin, creating a unique
activation/regulation loop of potential importance in a variety of cell
fate and functions. Here we studied the involvement of the p42/p44 MAPK
pathway in such regulation. Using HepG2 cells transfected with
fur P1 LUC (luciferase) promoter construct, we observed that forced expression of a dominant negative mutant form of
the small G protein p21ras (RasN17) inhibited TGF
1-induced
fur gene transcription, suggesting the involvement of the
p42/p44 MAPK cascade. In addition, TGF
induced sustained
activation/phosphorylation of endogenous p42/p44 MAPK. Further-more,
the role of MAPK cascade in fur gene transcription was
highlighted by the use of the MEK1/2 inhibitors, PD98059 or U0126, or
co-expression of a p44 antisense construct that repressed the induction
of fur promoter transactivation. Conversely, overexpression of a constitutively active form of MEK1 increased unstimulated, TGF
1-stimulated, and Smad2-stimulated promoter P1 transactivation, and the universal Smad inhibitor, Smad7, inhibited this effect. Activation of Smad2 by MEK1 or TGF
1 resulted in an enhanced nuclear localization of Smad2, which was inhibited upon blocking MEK1 activity.
Our findings clearly show that the activation of the p42/p44 MAPK
pathway is involved in fur gene expression and led us to
propose a co-operative model whereby TGF
1-induced receptor activation stimulates not only a Smad pathway but also a parallel p42/p44 MAPK pathway that targets Smad2 for an increased nuclear translocation and enhanced fur gene transactivation. Such
an uncovered mechanism may be a key determinant for the regulation of
furin in embryogenesis and growth-related physiopathological conditions.
 |
INTRODUCTION |
Furin is a mammalian subtilisin/Kex2p-like
Ca2+-dependant endoprotease involved in the processing of
various types of higher molecular mass precursor substrates, containing
the minimal basic amino acid RXXR recognition motif. This
prototype of the pro-protein convertase family (for reviews, see Refs.
1 and 2) is primarily located in the trans-Golgi apparatus
(3), although some proportion of the furin molecules can recycle from
the cell membrane to endosomes (4). The biological importance of this
convertase stems from the large number and variety of bioactive
proteins and peptides that can be generated through its activity. These
include key molecules involved in normal and physiopathological
conditions including growth/differentiation processes. Furin cleaves
C-terminal to an unique processing site (RX(K/R)R) found in
many growth/differentiation-related peptides and proteins including
TGF
,1 activin A, BMP
family members, Nodal, lefty-1, and lefty-2 as well as growth
factor pro-receptors such as insulin-like growth factor receptor and
the hepatocyte growth factor receptor (c-Met) (2, 5, 6). Silencing
of the expression of mouse furin results in embryonic lethality because
of hemodynamic insufficiency associated with several development
defects including disruption of development of the heart and vascular
system and failure to undergo axial rotation (7). These findings
highlight the role of furin in growth and development and in the
physiological maturation of substrates involved in these processes
including members of the TGF
family.
The results from previous studies have demonstrated that pro-TGF
1 is
efficiently processed by furin releasing the genuine mature growth
factor (8) and that among the pro-protein convertase members, furin
more closely satisfies the requirements needed for an authentic TGF
1
converting enzyme (9). In fibroblastic and synovial cells, the furin
cleavage product, TGF
1, up-regulated gene expression of its own
converting enzyme, resulting in an increase in endogenous TGF
1
processing activity and release of the bioactive peptide (10). TGF
1
did not increase furin mRNA stability and treatment of synovial
cells with actinomycin D, before TGF
1 addition prevented the
increase in fur gene expression. This observation suggested
that furin concentrations could be regulated at the transcriptional
level, resulting in the increase in local concentrations of bioactive
growth factors. However, the molecular mechanisms by which TGF
1
exerts its effects have not been fully elucidated.
In the last few years significant progress has been made in the
signaling mechanisms utilized by TGF
1. A major discovery comes from
the recent uncovering and cloning of specific Smad signaling proteins
consisting of pathway-restricted Smads (Smad2 and Smad3), the common
mediator Smad4, and the inhibitory Smads (Smad6 and Smad7) (for reviews
see Refs. 11-13) that directly inhibit the TGF
type I receptor
serine-threonine kinase and the transcriptional machinery. TGF
signals through sequential activation of two cell surface
serine-threonine kinase receptors, which phosphorylate Smad2 and Smad3
within their conserved C-terminal SSXS motif (14, 15). These
activated Smads, together with Smad4, translocate to the nucleus and,
in association with other transcription factors, activate the
transcription of target genes (16, 17). Among the participating
transcription factors are the winged helix factor FAST (now known as
FoxH1) (18) in the case of Smad2 (19) or AP-1 in the case of Smad3
(reviewed in Refs. 20-22). Naturally occurring inhibitors, Smad6 and
Smad7, block and hence control TGF
superfamily signaling by
competitively interacting with the activated type I receptors (23,
24).
As increasing information is collected regarding the detailed molecular
mechanism of Smad protein signaling, a number of functional interactions between these proteins and other signaling pathways have
been reported. For example, recent work has demonstrated that the
linker region of BMP pathway-restricted Smad1 was phosphorylated by
ERK2 (25), a member of the classic ERK-activated protein kinase
pathway, leading to the inhibition of nuclear translocation of the
Smad1-Smad4. In contrast, other studies have demonstrated positive
functional interaction between the two stress-activated protein kinase
pathways and Smads. For instance, it has been demonstrated that the
mitogen-activated protein kinase kinase kinase-1 (MEKK-1), an upstream
activator of the stress-activated protein kinase/c-Jun N-terminal
kinase pathway, enhances Smad protein transcriptional co-activator
interactions in endothelial cells (26). Also, other groups have
demonstrated that TGF
1 activates Smad and TAK1 pathways, resulting
in the formation of an active transcription complex composed of
Smad3-Smad4 and the p38 nuclear target ATF-2 (27, 28).
In a recent study, we provided evidence for the central role of Smads
in the transcriptional activation of the TGF
1-inducible fur P1 promoter activity (29). Using HepG2 cells transfected with LUC (luciferase) promoter constructs, we observed that
among the three furin promoters, the P1 promoter was the strongest and the most sensitive to TGF
1 and that Smads were essential for mediating such responsiveness. We also observed that the proximal P1
promoter region (positions
8734 to
7925) that contains one SBE (Smad binding element) and one ARE (activin-responsive
element) binding site carries most of the Smad responsiveness. These
results highlight the central role of Smads in the expression of furin, an important gear of the complex TGF
1 maturation/activation machinery.
In light of the emerging evidence for the interactions between the Smad
and the MAPK pathways and the role of furin in growth and
differentiation events, it was of interest to explore the possible
integration between these two pathways for the regulation of this
convertase. Using HepG2 cells transfected with fur P1 LUC (luciferase) promoter construct, we observed that forced
expression of a dominant negative mutant of the small G protein
p21ras (RasN17) inhibited TGF
1-induced fur gene
transcription. Furthermore, the role of the p42/p44 MAPK cascade in
fur gene transcription was emphasized by the use of the
MEK1/2 inhibitors, PD98059 or U0126, or co-expression of a p44
antisense construct that blunted the induction of fur gene
transcription by TGF
1. Conversely, forced expression of a
constitutively active form of MEK1 (MEKA) increased unstimulated,
TGF
1-stimulated, and Smad-stimulated promoter P1 transactivation,
and the universal Smad inhibitor, Smad7, inhibited this effect. Our
findings clearly show that activation of the p42/p44 MAPK pathway is
involved in fur gene expression and suggest functional
interactions between the Smad and the p42/p44 MAPK cascade pathway in
this regulation.
 |
EXPERIMENTAL PROCEDURES |
Cell Culture--
The human liver cell line (HepG2) was obtained
from American Type Culture Collection and maintained in a complete
medium composed of minimal essential medium (Life Technologies,
Inc.) with 10% fetal bovine serum (Intergen Company, Rochester,
NY) and 40 µg/ml garamycin (Shering Canada Inc., Pointe-Claire,
Canada). The HepG2 cells were trypsinized and reseeded twice weekly.
Materials--
Recombinant human TGF
1 was a generous gift
from Dr. Anthony F. Purchio. Dr. Torik A. Y. Ayoubi generously
provided human promoter luciferase constructs pGL2-P1. Plasmids pCMV5B
(empty vector), pCMV5B-FlagSmad1, and pCMV5B/mSmad4 were described
previously (14, 30). Plasmid pCMV5-Smad7 (Smad7) was kindly provided by
Dr. Dean Falb (Millennium Pharmaceuticals Inc., Cambridge, MA).
Constructions of Rous sarcoma virus Neo (control vector) and Rous
sarcoma virus Ras Asn-17 (dominant negative of p21ras, RasN17)
were described previously (31). MEKA subcloned into expression vector
pECE and p44mapk antisense in pcDNA (kindly provided by
Dr. Jacques Pouysségur) were described previously (32, 33).
Finally, plasmids pCSMT (empty vector) and pCSMT-FAST (FAST-1), now
known as FoxH1 (18), were a generous gift from Dr. Malcolm Whitman.
Antiserum E1B, which specifically recognizes p42/p44 MAPK on Western
blots, was a kind gift from Drs. Fergus McKenzie and Jacques
Pouysségur (34). Rabbit polyclonal antibodies directed against
phosphorylated and active forms of p42/p44 MAPK were from New England
Biolabs (Mississauga, Canada). The MEK1/2 inhibitors PD98059 and U0126 were purchased from Calbiochem-Novabiochem Corp. (San Diego, CA). Goat
polyclonal anti-Smad2 antibodies were purchased from Santa Cruz
Biotechnology. Inc. (Santa Cruz, CA) and revealed with
fluorescein-conjugated rabbit affinity purified F(ab')2 fragment to
goat IgG (ICN Biochemicals, Costa Mesa, CA).
Luciferase Assays--
HepG2 cells were transiently transfected
by CaPO4 precipitation technique using a mammalian cell
transfection kit (Specialty Media Inc., Lavallette, NJ) as described
previously (35). Briefly, 24 h prior to transfection, HepG2 cells
were plated using a plating density of 27,000 cells/well in 24-well
plates (Falcon Labware, Mississauga, Canada) in complete medium. The
cells were fed fresh complete medium for 3-4 h before transfection.
HepG2 cells were transfected with 0.5 µg plasmid/well for each
plasmid, and the cells in control wells were transfected with
appropriate control vectors to compensate for potential squelching.
Gently vortexed DNA/CaPO4 precipitate suspension was added
slowly, dropwise, while gently swirling the medium in the plate. The
plates were returned to the incubator until the next morning when the
cells were rinsed with PBS and serum-starved (0.2% fetal bovine serum)
for 6-8 h prior to overnight stimulation with 0 or 5 ng/ml TGF
1. In
experiments using PD98059, the MEK1-specific inhibitor was added
simultaneously with TGF
1 to a final concentration of 10 µM, and control cells received a final concentration of
Me2SO vehicle of 0.05%. The cells were then lysed, and
luciferase activity was measured as described previously (35).
-Galactosidase activity was monitored as an internal control of
transfection efficiency using a
-galactosidase enzyme assay system
(Promega, Madison, WI). The results were expressed as ratios of
luciferase activity over
-galactosidase activity.
Northern Analysis--
Total RNA was extracted from cultured
cells according to the TRI-Reagent protocol described previously
(Molecular Research Center Inc., Cincinnati, OH). Northern analysis of
furin gene expression and measure of RNA loading and integrity used in
this publication has previously been extensively detailed elsewhere (10). Signal intensity was quantitated by densitometry with a Amersham
Pharmacia Biotech LKB Ultrascan XL. The densitometric values are
expressed as the ratio of fur/GAPDH densitometric
quantification with control values set at 1.
Protein Expression and Immunoblotting--
As described
previously, the cells were lysed in SDS sample buffer (62.5 mM Tris-HCl, pH 6.8, 2.3% SDS, 10% glycerol, 5%
-mercaptoethanol, 0.005% bromphenol blue, 1 mM
phenylmethylsulfonyl fluoride); proteins (40 µg) from whole cell
lysates were separated by SDS-polyacrylamide gel electrophoresis in
10% gels (36). The proteins were detected immunologically following
electrotransfer onto nitrocellulose membranes. The blots were then
incubated with different antibodies in blocking solution overnight at
4 °C and then incubated with horseradish peroxidase-conjugated goat
anti-mouse or anti-rabbit (1:1000) IgG in blocking solution for 1 h. The blots were visualized by the Amersham Pharmacia Biotech ECL
system. The protein concentrations were measured using a modified Lowry
procedure with bovine serum albumin as standard (37).
Indirect Immunofluorescence Microscopy--
HepG2 cells were
plated at a density of 125,000 cells/well in 6-well plates (Falcon
Labware) on sterile coverslips in complete medium and then transfected
in suspension with 2 µg of Smad2 DNA construct/well with 4 µl/well
of FuGENETM6 (Roche Molecular Biochemicals) according to
manufacturer's protocol. Twenty four hours post-transfection, HepG2
cells were serum-starved (0.2% fetal bovine serum) overnight prior to
30 min of preincubation with 10 µM of PD98059 or 0.05%
Me2SO vehicle followed by a 1-h incubation with 10 ng/ml
TGF
1. Transfected and stimulated HepG2 cells were then prepared for
immunofluorescence staining as described previously (38). Briefly, the
cells were washed with cooled PBS and then fixed for 15 min in
precooled (
20 °C) methanol/acetone (30/70). After a 15-min
rehydration in PBS, the cells were permeabilized in PBS with 0.25%
Triton for 5 min, and nonspecific binding was blocked by incubation for
20 min in PBS with 2% bovine serum albumin. Fixed cells were then
incubated for 1 h with anti-Smad2 primary antibody (1:50). The
cells were again washed five times with PBS followed by incubation in
PBS with bovine serum albumin for 60 min with fluorescein-conjugated
second antibody (anti-goat, 1:100). Finally, the cells were washed five
times and stained 5 min with 0.025% Evan's Blue (Sigma) and then
washed five times with PBS. Smad2 cellular localization was examined
under epifluorescent illumination with the relevant excitation-emission
filters. In these conditions, endogenous Smad2 proteins were not
detected. For each cell treatments, an average of 20 random
fields/slide were analyzed. The scoring was performed blindly by two
independent investigators.
 |
RESULTS |
Involvement of the Ras-MAPK Cascade in TGF
1-induced fur Gene
Activation--
Previous reports have demonstrated in several cell
systems that TGF
1 increased furin mRNA expression starting
3 h after stimulation, and the peak effect was observed at 18-24
h. No effects were observed at the earlier 1-h time point (10, 29).
Treatment of cells with actinomycin D before or after stimulation
indicated that furin gene expression was regulated at the
transcriptional level. As an attempt to determine the nature of the
signaling response involved, we have examined the involvement of the
Smad transducers. We have shown that Smad2 and Smad4, possibly in
complex with the winged helix transcription factor FAST (FoxH1),
participate in the constitutive and TGF
1-inducible transactivation
of the fur P1 promoter in HepG2 cells (29). Because TGF
1
is widely documented to be implicated in the regulatory mechanisms of
cellular growth and differentiation (39-41), it was of interest to
determine whether the classical proliferation/differentiation module
Ras/Raf/MEK/p42/p44 MAPK is also involved in fur P1 promoter
transactivation. For this, we co-transfected HepG2 cells with a pGL2-P1
luciferase reporter gene and either a control or a dominant interfering
p21ras vector (RasN17), and cells were stimulated overnight in
the presence (5 ng/ml) or the absence of TGF
1. We observed that
RasN17 inhibited both constitutive (77% inhibition) and
TGF
1-induced (91% inhibition) P1 promoter activation (Fig.
1). These results indicate that
Ras-dependent signaling pathways are involved in the
regulation of fur P1 promoter.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 1.
Involvement of Ras in
TGF 1 signaling. Transient co-transfection
of HepG2 cells with furin promoter P1 luciferase construct (pGL2-P1)
and either Rous sarcoma virus Neo (control vector) or dominant negative
of p21ras (RasN17). The cells were incubated overnight in the
absence (white bars) or the presence (black bars)
of TGF 1 (5 ng/ml). Luciferase activity is expressed as the fold
increase relative to the unstimulated control. The data are expressed
as the means ± S.E. (n = 4).
|
|
In addition to the p42/p44 MAPK cascade, Ras also controls other
signaling pathways such as those linked to phosphatidylinositol 3-kinase or Rac/Rho proteins (42). Hence, to specifically analyze the
contribution of the p42/p44 MAPK cascade in TGF
1-induced P1 promoter
activation, we first examined the phosphorylation of p42/p44 isoforms
in cells stimulated by TGF
. The cell lysates were prepared from
serum-starved HepG2 cells stimulated for the indicated time periods
with 5 ng/ml TGF
1. Western blot analysis with an antibody
recognizing the biophosphorylated and active MAPK isoforms revealed
that TGF
1 induces a relatively small but reproducible increase in
MAPK activities within 30 min (1.5 ± 0.5-fold increase;
p
0,05; n = 3) with a maximal effect
observed 2 h post-stimulation (7.3 ± 2.7-fold increase;
p
0,05; n = 3) (Fig.
2). Therefore, the changes in p42/p44
phosphorylation by TGF
precede the previously reported up-regulation
in furin mRNA levels (10).

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 2.
Phosphorylation of p42/p44 MAPK by
TGF 1. A, 40 µg of HepG2 cell
extracts were harvested at different time periods (5 min to 4 h)
after TGF 1 addition (5 ng/ml), and p42/p44 MAPK phosphorylation was
determined in renatured SDS-polyacrylamide and Western blotting onto
nitrocellulose membranes. B, densitometric analysis of
phosphorylated p42/p44 versus total p42/p44. p42/p44 MAPK
phosphorylation was visualized with an antibody specifically
recognizing p42 and p44 phosphorylated on the TEY motif and compared
with antiserum E1B, which specifically recognizes total p42 and p44
MAPK on Western blots. The data are expressed as the fold increase over
unstimulated cells. This is a representative experiment of three.
ctl, control.
|
|
Next, we employed a pharmacological inhibitor of MEK1/2, PD98059 that
prevents the activation of MEK1/2, thereby inhibiting p42/p44
phosphorylation. In the presence of PD98059, the ability of TGF
1 to
induce P1 promoter transcription is dose-dependently inhibited (Fig. 3A). As a
control, the Me2SO vehicle, at the concentration used in
these experiments (0.05%), did not alter either basal or induced P1
transactivation in HepG2 cells. To confirm that these effects were
through the inhibition of MEK, the experiments were repeated using a
structurally unrelated MEK inhibitor, U0126, which specifically
inhibits the function of activated MEK1/2 (43). The effects of this
inhibitor were similar to those observed using PD98059 (Fig.
3B), strongly suggesting that the effects of PD98059 are due
to its ability to inhibit MEK, thereby inhibiting TGF
-induced phosphorylation of downstream p42/p44 kinases. To confirm this, p42/p44
phosphorylation was measured by Western blot assays. As demonstrated in
Fig. 3C, low concentrations (2.5 µM and10
µM) of PD98059 or U0126 efficiently suppressed
TGF
-induced p42/p44 phosphorylation.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 3.
Regulation of
TGF 1-induced fur gene
transcription by the p42/p44 MAPK module. HepG2 cells were
incubated overnight in the absence (white bars) or the
presence (black bars) of TGF 1 (5 ng/ml). Decreasing
concentrations of MEK-specific inhibitors PD98059 or U0126 were added
simultaneously and vehicle control cells received a final concentration
of 0.05% Me2SO (D). In A and
B, the cells were transiently transfected with furin
promoter P1 luciferase construct 24 h before TGF addition.
A, PD98059 treatment; B, U0126 treatment. The
data are expressed as the means ± S.E. (n = 6). In parallel experiments, C p42/p44 phosphorylation was
analyzed as described above. D, mRNA was analyzed by
Northern blot. The results are expressed as ratios of
fur:GAPDH with the control value set at 1. BN
M, medium.
|
|
Northern blot analysis was also performed to examine the effects of MEK
inhibitors on TGF
1-induction of furin mRNA expression. As shown
in Fig. 3D, the addition of 10 µM of PD98059
or U0126 inhibited the ability of TGF
to induce furin mRNA
expression by 48 and 77%, respectively. So far, our results indicate
that TGF
1 induction of furin gene expression is mediated through the MEK/p42/p44 MAPK pathway as one of the events downstream of Ras.
Inhibition of the MEK/MAPK Cascade Blocks Smad-induced fur Promoter
Activation--
Because both Smads (29) and p42/p44 MAPKs are involved
in fur regulation, we next investigated the possible
interplay between these signaling pathways. HepG2 cells were
transfected with pCSMT plasmid encoding FAST-1, a forkhead signal
transducer known to interact with Smad2-Smad4 complexes, and the cells
were incubated in the presence or the absence of the MEK inhibitor
PD98059. As observed in Fig.
4A, pharmacological inhibition
of MEK resulted in a concentration-dependent reduction of
TGF
1/FAST-induced fur P1 promoter transactivation.
Although ectopically expressed FAST exhibits potent transcriptional
activation in the presence of TGF
1, low concentrations of PD98059
(less than 10 µM) were sufficient to efficiently block
such activation. To more directly investigate the impact of MEK1p42/p44
MAPK cascade blockage on Smad-induced transactivation, HepG2 cells were
next transfected with various combinations of Smads. In these
experiments, the Smad1-Smad4 combination was used as a control because
Smad1 is a BMP-specific pathway-restricted Smad (30, 44). As expected,
in the presence of Smad1, no significant increase in luciferase
activity was measured in response to TGF
1 stimulation in HepG2
cells. Conversely, forced expression of Smad2 or Smad4 alone or in
combination significantly increased TGF
1-induced fur P1
promoter transcriptional activities, which is clearly inhibited by
MEK1/2 inhibitor PD98059 at a concentration of 10 µM
(Fig. 4B). Consistent with this, co-transfection with of a
p44 antisense construct, which has been found to reduce up to 90% of
both p44MAPK and p42MAPK expression (33),
robustly suppressed TGF
1-, Smad-, or FAST-1-stimulated luciferase
expression (Fig. 4C). Taken together, these observations suggest functional cross-talk interactions between MEK1 or p42/p44 MAPKs and the Smad2-Smad4 pathway for fur promoter
activation.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 4.
Regulation of Smad-induced
fur P1 promoter transactivation by the p42/p44 MAPK
module. HepG2 cells were transiently co-transfected with
fur P1 promoter construct pGL2-P1 and either the winged
helix FAST (FoxH1) transcription factor construct pCSMT-FAST-1
(A), combinations of Smad1 or Smad2 with common Smad, Smad4
(B), or Smad2 or FAST-1 in the presence or the absence of
p44-AS construct or control pcDNA vector (C). The cells
were incubated overnight in the absence (white bars) or the
presence (black) of TGF 1 (5 ng/ml). MEK1 specific
inhibitor PD98059 (PD) was added simultaneously to a final
concentration of 10 µM in B, and the control
cells were incubated in medium only (M) or Me2SO
vehicle (D). Luciferase activity is expressed as
fold-increase relative to the unstimulated control. The data are
expressed as the means ± S.E. (n = 3-7).
|
|
Effect of MEKA on Smad-regulated fur Gene Transcription--
To
provide further insights into the possible interplay existing between
the classic p42/p44 kinase cascade and Smad2-dependent pathway, HepG2 cells were co-transfected with or without MEKA, Smad2,
or Smad4, and pGL2-P1 promoter luciferase activity was measured. As
shown in Fig. 5A, MEKA
increased constitutive and TGF
1-induced fur promoter P1
transactivation by 0.9- and 9.8-fold, respectively. The highest
transactivation was observed when Smad2 (18.0 ± 0.9-fold) and
Smad4 (43.4 ± 9.6-fold) were combined with MEKA in the presence
of TGF
1. To determine the contribution of receptor-activated Smads
in MEK1-induced activation of fur promoter, MEKA was
co-expressed with Smad7, a Smad antagonist that interferes with the
phosphorylation/activation of Smad2 and Smad3 (24) or Smad2(3SA), a
dominant negative form of Smad 2 (14). The basal levels of luciferase
activity observed as well as the increase in the presence of MEKA alone
probably reflects endogenous TGF
1 production by HepG2 cells, as
previously demonstrated by us (29) and others (45). As shown in Fig.
5B, TGF
1, MEKA, and TGF
1 plus MEKA-induced activation
of fur P1 promoter were potently inhibited by co-expression
of Smad7, indicating that TGF
1 receptor-activated Smad proteins are
indeed playing a role in MEK1-mediated transcriptional activation of
P1. Moreover, Smad2(3SA) blocked MEKA-induced transactivation in the
presence of TGF
(Fig. 5C), suggesting cooperation between MEKA and activated endogenous Smad2. Taken together, these results indicate that maximal transcriptional activation of pGL2-P1 promoter by
TGF
1 stimulation requires the action of p42/p44 MAPKs as well as the
TGF
1-specific receptor-regulated Smad2 and common Smad4.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 5.
Effect of MEKA on Smad-regulated
fur gene transcription. HepG2 cells were
transiently co-transfected with fur P1 promoter construct
and either overexpressed Smad2, Smad4, MEKA plasmid constructs or
individual Smads in combination with MEKA (A), combined
overexpressed MEKA with inhibitor Smad7 construct (B), or
either overexpressed Smad2 or Smad4 or individual Smads in combination
with MEKA in the presence or the absence of Smad2-3SA (C).
The cells were incubated overnight in the absence (white
bars) or presence (black bars) of TGF 1 (5 ng/ml).
Luciferase activity representing fur P1 promoter activation
is expressed as the fold increase relative to the unstimulated control.
The data are expressed as the means ± S.E. (n = 3-5).
|
|
Involvement of MEK1 in TGF
-induced Smad2 Nuclear
Translocation--
It has been previously demonstrated that Smad2
translocates to the nuclear compartment in response to the activated
TGF
type I receptor, TGRI (14) or by TGF
1 stimulation (46). To
determine whether disruption of the MAPK pathway can alter the
subcellular localization of Smad2, we used indirect immunofluorescence
microscopy with Smad2-specific antibodies. HepG2 cells were transfected
with Smad2 and were treated with 10 ng/ml TGF
1 for 1 h. As
expected, Smad2 in unstimulated cells demonstrated a diffuse, mainly
cytoplasmic staining (47), a pattern consistent with overexpressed and
nonactivated Smad2. When HepG2 cells were stimulated with TGF
1, up
to 49.6 ± 3.1% of them exhibited a predominantly nuclear
Smad2-specific staining compared with 10.1 ± 1.4% for control
unstimulated cells. Interestingly, the use of PD98059 significantly
reduced (78%) the amount of TGF
-induced Smad2 nuclear staining with
19.0 ± 0.9% of cells that exhibited a predominant nuclear
staining (Fig. 6). To further support the
role of MEK1 in Smad2 subcellular localization, Smad2 was
co-transfected with constitutively active MEK1 mutant. Interestingly,
overexpressing MEKA in unstimulated HepG2 cells results in 3.7-fold
increase in Smad2 nuclear localization that is further increased to
5.3-fold upon TGF
1 stimulation (Fig. 6B). These
observations clearly demonstrated functional interaction between Smad2
and MEK/p42/p44 MAPK cascade.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 6.
TGF 1-induced Smad2
nuclear translocation is modulated by the MEK1/ERK MAPK module.
Immunofluorescence was performed on monolayers of HepG2 cells
transfected with Smad2 construct and treated as indicated. The cells
were fixed, permeabilized, stained with goat anti-Smad2 polyclonal
antibody, and then visualized with secondary antibodies coupled to
fluorescein isothiocyanate by fluorescence microscopy. A,
regions of the confluent monolayer containing representative stained
cells are shown (adjacent untransfected cells are revealed only by
Evan's Blue stain). B, graphic representation of
three independent experiments expressed as the percentage of positive
nuclei following ligand treatment. The data are expressed as the
means ± S.E. (n = 3-6). Student t
test: *, p = 0.016; **, p = <0.001.
|
|
 |
DISCUSSION |
The findings presented herein clearly show that TGF
1-induced
receptor activation stimulates not only a Smad pathway but also a
parallel p42/p44 MAPK pathway that targets Smad2 for an increased nuclear translocation and enhanced fur gene transactivation.
Even though other reports such as the one from Hayashida et
al. (48) have raised the possibility of interactions between the
Smad and MAPK pathways for TGF
-stimulated collagen gene expression,
few studies have indeed reported positive cross-talk between
the growth/differentiation MAPK pathway and the Smad pathway for the
regulation of TGF
-related functions. For instance, work from de
Caestecker et al. (46) indicated that hepatocyte growth
factor and epidermal growth factor mediate Smad-dependent
reporter gene activation and induce phosphorylation of Smad 2 by
kinases downstream of MEK1. More recently, Watanabe et al.
(49) have shown that in differentiated chondrocytes, rapid and
sustained activation of both p42/p44 and p38 MAPK is required for high
levels of aggrecan gene expression, whereas Smad 2 was also involved in
the initial activation of this gene that occurs in undifferentiated
cells. In contrast, Kretzschmar et al. (25) have
demonstrated that the MAPK/ERK1/2 pathway can negatively
regulate the BMP-Smad-1-dependent transcriptional response. Also, results from Brown et al. (26) indicated that the
stress-activated SAPK/JNK pathway, but not the p42/p44 MAPK pathway,
can activate Smad-2-mediated transcriptional activation in bovine
endothelial cells. Although Yue and Mulder (50) have suggested that the Ras/MAPK pathways are essential for TGF
3 induction of TGF
1 in lung and intestinal epithelial cells, they proposed that Smads only
contribute to this biological response in an indirect manner. The exact
reasons for these discrepancies remain unknown, but it is clear that
multiple interactions between MAPK and Smad pathways can occur
depending on the cell type and possibly the extent of MAPK activation.
To determine whether the classical p42/p44 MAPK cascade is involved in
TGF
1-induced activation of the fur gene, our first initiative was to determine whether the ability of TGF
1 to stimulate fur gene expression was a
p21ras-dependent or p21ras-independent
mechanism. Interestingly, constitutive and TGF
1-induced transcription of the reporter gene was efficiently inhibited by dominant negative RasN17 expression in HepG2 cells. Partial blockage of
constitutive P1 promoter activity may reflect the requirement of
p42/p44 MAPK cascade or other Ras effectors such as those linked to
phosphatidylinositol 3-kinases for basal fur
transactivation. Also, it is possible that the inhibition of basal P1
promoter activation by Ras DN is due to interference with basal
activation of TGF
signal transduction pathways. In support of this,
recent experiments using TGF
-neutralizing antibodies have
demonstrated that autocrine production of TGF
accounts for 45% of
basal furin P1 promoter activation in the HepG2 cell system (29). The
requirement of Ras for TGF
-induced fur transactivation
extends a previous study that identified other GTPases of the Rho
family as intermediates of TGF
1-initiated signaling leading to
transcriptional activation of a TGF
reporter construct (p3TP-Lux) in
the same cell line (51).
In addition to the fur gene, Ras has been shown to be
involved in the expression of other genes/proteins regulated by TGF
. For example, RasN17 was shown to inhibit the autoinduction of TGF
1
in lung and intestinal epithelial cells (50), the TGF
-induced cell
cycle-related p27Kip1 and p21 Cip1 in intestinal epithelial cells (52),
and TGF
-induced urokinase expression in transformed keratinocytes
(53). In this context, the participation of Ras in the cellular cascade
leading to the regulation of the fur gene by TGF
would be
consistent with the view of Ras as an integrator of a wide variety of
TGF
-related growth/differentiation events.
Although Ras is involved in the activation of multiple pathways, we
next demonstrated that the p42/p44 MAPK pathway is also involved in
TGF
-induced fur activation. In initial experiments, we
have observed that TGF
1 stimulation of HepG2 cells results in a
relatively delayed but sustained p42/p44 MAPK phosphorylation. Next, we
observed that a biochemical blockade of p42/p44 MAPK activation or
mRNA reduction through antisense technology blocked TGF
1-induced
transcriptional activation of furin P1 promoter and activation of
p42/p44 MAPKs. In contrast, MEKA increased unstimulated and
TGF
1-stimulated P1 transactivation. Taken together, these observations provide strong evidence that the Ras-MEKp42/p44 MAPK signaling plays an important role in the regulation of fur
gene expression. In a similar way, the absolute requirement of p42/p44 MAPKs cascade in TGF
1-induced functions such as the attenuation of
haptoglobin gene expression in intestinal epithelial cells has been
reported (54).
In our study, the delayed (starting 30 min) and sustained stimulation
of p42/p44 MAPK phosphorylation by TGF
is consistent with a possible
indirect mechanism of activation. In fact, most studies using different
cell types including phorbol 12-myristate 13-acetate-differentiated
THP-1 cells, epithelial cells, or chondrocytes have reported more rapid
activation of p44 MAPK occurring within 5-10 min of TGF
1 addition
(49, 55, 56). In human mesanglial cells, however, a more delayed (30 min) kinetic of activation has been observed (48). Although the
significance of this difference in timing of activation has not been
elucidated, Hayashida et al. (48) have ruled out the
involvement of new protein synthesis and/or release of platelet-derived
growth factor for the delayed activation observed in mesanglial cells.
In our system, platelet-derived growth factor would unlikely mediate
the observed early p42/p44 activation because the kinetic of
platelet-derived growth factor production in cells typically occurs
later (i.e. at 2-4-h time points) after TGF
stimulation
(57, 58). However, it would appear logical to propose that autocrine
regulation of growth factors by TGF
accounts for at least some of
the signal amplification observed 2-4 h after TGF
stimulation.
The mechanisms regulating fur expression are not fully
understood. In previous studies, we found that TGF
1-increased
fur gene regulation occurs at the level of gene
transcription (10) and that Smad2 possibly with winged helix
transcription factor FAST (FoxH1) participate in this transactivation
(29). Here we demonstrate that forced expression of Smad2-Smad4 or MEKA
leads to the activation of the fur P1 promoter, mimicking
the effect of TGF
1. In addition, MEKA-induced transactivation was
abrogated in cells co-expressing the Smad inhibitor Smad7, and
similarly, Smad2-Smad4-induced transactivation was blocked using
chemical MEK inhibitors. This argues that both Smad and p42/p44 MAPK
pathways are essential for mediating TGF
1-induced transactivation of
furin. In this regard, several cross-talk interactions are possible
between the Smad and MAPK pathways, depending on the cellular
environment and the targeted biological function (21, 25, 26, 46, 49,
59). As more information is being gathered regarding direct involvement
of the stress-activated protein kinase/c-Jun N-terminal kinase pathway
in Smad activation, little information is available regarding direct
involvement of the p42/p44 MAPK pathway. In our study, we observed that
inhibition of MEK by PD98059 blocked most of the enhanced Smad-2
nuclear localization induced by TGF
. In contrast, activation of
p42/p44 MAPKs by activated MEK1 resulted in an enhanced nuclear
localization of Smad2. One explanation for this cross-talk is a direct
interaction between MEK1 or p42/p44 MAPKs and Smad2. It has been
recently demonstrated that growth factors, namely hepatocyte growth
factor and epidermal growth factor, can also mediate both
Smad-dependent 3TP-lux reporter gene activation and nuclear
translocation of Smad2 (46). This correlates with an increase of Smad2
phosphorylation that is markedly reduced in the absence of the
C-terminal SSXS motif of Smad2, which is the site of TGF
type I receptor-induced phosphorylation. It has been shown that Smad7
can bind to type I TGF
1 receptor and inhibits its capacity to
phosphorylate Smad2 (22, 23). In our study, the ability of Smad7 to
inhibit MEK1-mediated transcriptional activation suggests that
phosphorylation at the SSXS motif is needed for MEKA-induced
activation of Smad2. This does not rule out the possibility that other
potential phosphorylation motifs for the proline-directed kinases
MEK/p42/p44 MAPK found within the Smad2 linker region may also
participate in Smad activation as demonstrated for Smad1 (25, 59).
It was surprising to observe an enhanced Smad2 nuclear localization by
MEKA in the absence of exogenous TGF
stimulation. One possible
explanation for this is the induction of autocrine TGF
production by
activated MEK. In support of this, a recent study by Yue and Mulder
(50) indicated a requirement of Ras/MAPK pathway for the induction of
TGF
1 by TGF
. In this context, p42/p44 MAPK activation by MEKA may
result in the induction of TGF
that in turn activates the Smad
pathway for an enhanced Smad2 nuclear localization and increased furin
expression. Also, because nuclear translocation of the Smad3 proteins
was shown to occur through direct binding to the nuclear transporter
importin
(60), it would be tempting to speculate that the increase
in Smad nuclear translocation comes from direct or indirect
modification by activated MEK/p42/p44 kinases of proteins involved in
Smad nuclear transport. In this regard, phosphorylation of the importin
58/97 heterodimer by activated CK2 kinases was shown to increase its
affinity for the ligand, leading to enhanced nuclear transport of the
complex (61).
Evidence is now accumulating favoring a crucial role for furin in
various health and disease states including proliferative and
inflammatory diseases (10, 62). It was demonstrated that the
transcription of the fur gene can be regulated by TGF
in several cells generating an enzyme/substrate amplification loop that
leads to an increase in local concentrations of TGF
1 (10). Also,
Hoshino et al. (63) have demonstrated changes in the
expression of furin and TGF
in regenerating and differentiating
hepatocytes as well as developmental changes in furin expression in rat
pancreatic islets (64). These observations suggested that furin
concentrations could be regulated in growth/differentiation events
leading to increased bioactive growth-related factors. In addition to
members of the vast TGF
family, these precursor proteins include,
among others, several key growth factor precursors such as
platelet-derived growth factor A and B chains, growth factor
proreceptors such as the insulin receptor and the hepatocyte growth
factor receptor (c-Met), several integrin
-subunits, and cadherin
family members that share a common RX(K/R)R furin
recognition motif at the junction between the proregion and the mature
polypeptide (65). The findings outlined in the present study support
the involvement of MEK/p42/p44 MAPK signaling in TGF
1-induced and
Smad-regulated furin expression. The cross-talk between these two
signaling pathways may serve as a growth/differentiation integration
signal involved in the bioavailability of a multitude of
furin-activated precursors, especially in developmental and
physiopathological conditions where temporal or sustained increase in
furin substrates were found coupled with changes in cell
proliferation/differentiation events. Our current model is depicted in
Fig. 7.

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 7.
Co-operative model for
TGF -activated fur gene
transactivation. The effects of TGF addition to cells results
in the activation of the TGF -specific Smad2/4 pathway are shown. In
parallel, T RII/I activation induces a rapid and sustained
phosphorylation of endogenous p42/p44 MAPK. Cross-talk with activated
MEK1/2 or downstream MAPK cascade elements enhances Smad2 nuclear
translocation where it may interact with DNA-binding proteins and
direct transcription of the fur gene. Increased
intracellular levels of furin will impact the bioactivation of multiple
growth/cell differentiation-related factors (10).
|
|
 |
ACKNOWLEDGEMENTS |
We thank Dr. Marie-France Langlois for help
with the CaPO4 transfection technique and Anne Vézina
for p42/p44 immunoblotting.
 |
FOOTNOTES |
*
This work was supported by a Canadian Arthritis Society
grant (to C. M. D.) and Medical Research Council of Canada
Grant MT-14461 (to C. M. D.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Immunology Div.,
Faculty of Medicine, Université de Sherbrooke, Sherbrooke, QC J1H
5N4, Canada. Tel.: 819-564-5289; Fax: 819-564-5215;
E-mail: cmdubois@courrier.usherb.ca.
Published, JBC Papers in Press, July 11, 2001, DOI 10.1074/jbc.M100093200
 |
ABBREVIATIONS |
The abbreviations used are:
TGF, transforming
growth factor;
BMP, bone morphogenic protein;
ERK, extracellular
signal-regulated kinase;
MEKK-1, mitogen-activated protein kinase
kinase kinase-1;
MAPK, mitogen-activated protein kinase;
MEK, MAPK/ERK
kinase;
PBS, phosphate-buffered saline.
 |
REFERENCES |
| 1.
|
Seidah, N. G.,
Day, R.,
Marcinkiewicz, M.,
and Chrétien, M.
(1998)
Ann. N. Y. Acad. Sci.
839,
9-24
|
| 2.
|
Nakayama, K.
(1997)
Biochem. J.
327,
625-635
|
| 3.
|
Vey, M.,
Schafer, W.,
Berghofer, S.,
Klenk, H. D.,
and Garten, W.
(1994)
J. Cell Biol.
127,
1829-1842
|
| 4.
|
Molloy, S. S.,
Anderson, E. D.,
Jean, F.,
and Thomas, G.
(1999)
Trends Cell Biol.
9,
28-35
|
| 5.
|
Constam, D. B.,
and Robertson, E. J.
(1999)
J. Cell Biol.
144,
139-149
|
| 6.
|
Constam, D. B.,
and Robertson, E. J.
(2000)
Development
127,
245-254
|
| 7.
|
Roebroek, A. J.,
Umans, L.,
Pauli, I. G.,
Robertson, E. J.,
van Leuven, F.,
Van de Ven, W. J.,
and Constam, D. B.
(1998)
Development
125,
4863-4876
|
| 8.
|
Dubois, C. M.,
Laprise, M. H.,
Blanchette, F.,
Gentry, L. E.,
and Leduc, R.
(1995)
J. Biol. Chem.
270,
10618-10624
|
| 9.
|
Dubois, C. M.,
Blanchette, F.,
Laprise, M. H.,
Leduc, R.,
Grondin, F.,
and Seidah, N. G.
(2001)
Am. J. Pathol.
158,
305-316
|
| 10.
|
Blanchette, F.,
Day, R.,
Dong, W.,
Laprise, M. H.,
and Dubois, C. M.
(1997)
J. Clin. Invest.
99,
1974-1983
|
| 11.
|
Attisano, L.,
and Wrana, J. L.
(1998)
Curr. Opin. Cell Biol.
10,
188-194
|
| 12.
|
Massagué, J.
(1998)
Annu. Rev. Biochem.
67,
753-791
|
| 13.
|
Heldin, C. H.,
Miyazono, K.,
and ten Dijke, P.
(1997)
Nature
390,
465-471
|
| 14.
|
Macias-Silva, M.,
Abdollah, S.,
Hoodless, P. A.,
Pirone, R.,
Attisano, L.,
and Wrana, J. L.
(1996)
Cell
87,
1215-1224
|
| 15.
|
Souchelnytskyi, S.,
Tamaki, K.,
Engstrom, U.,
Wernstedt, C.,
ten Dijke, P.,
and Heldin, C. H.
(1997)
J. Biol. Chem.
272,
28107-28115
|
| 16.
|
Zhang, Y.,
Feng, X.,
We, R.,
and Derynck, R.
(1996)
Nature
383,
168-172
|
| 17.
|
Nakao, A.,
Imamura, T.,
Souchelnytskyi, S.,
Kawabata, M.,
Ishisaki, A.,
Oeda, E.,
Tamaki, K.,
Hanai, J.,
Heldin, C. H.,
Miyazono, K.,
and ten Dijke, P.
(1997)
EMBO J.
16,
5353-5362
|
| 18.
|
Kaestner, K. H.,
Knochel, W.,
and Martinez, D. E.
(2000)
Genes Dev.
14,
142-146
|
| 19.
|
Chen, X.,
Rubock, M. J.,
and Whitman, M.
(1996)
Nature
383,
691-696
|
| 20.
|
Attisano, L.,
and Wrana, J. L.
(2000)
Curr. Opin. Cell Biol.
12,
235-243
|
| 21.
|
Zhang, Y.,
Feng, X. H.,
and Derynck, R.
(1998)
Nature
394,
909-913
|
| 22.
|
Liberati, N. T.,
Datto, M. B.,
Frederick, J. P.,
Shen, X.,
Wong, C.,
Rougier-Chapman, E. M.,
and Wang, X. F.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
4844-4849
|
| 23.
|
Imamura, T.,
Takase, M.,
Nishihara, A.,
Oeda, E.,
Hanai, J.,
Kawabata, M.,
and Miyazono, K.
(1997)
Nature
389,
622-626
|
| 24.
|
Hayashi, H.,
Abdollah, S.,
Qiu, Y.,
Cai, J.,
Xu, Y. Y.,
Grinnell, B. W.,
Richardson, M. A.,
Topper, J. N.,
Gimbrone, M. A, Jr.,
Wrana, J. L.,
and Falb, D.
(1997)
Cell.
89,
1165-1173
|
| 25.
|
Kretzschmar, M.,
Doody, J.,
and Massagué, J.
(1997)
Nature
389,
618-622
|
| 26.
|
Brown, J. D.,
DiChiara, M. R.,
Anderson, K. R.,
Gimbrone, M. A., Jr.,
and Topper, J. N.
(1999)
J. Biol. Chem.
274,
8797-8805
|
| 27.
|
Hanafusa, H.,
Ninomiya-Tsuji, J.,
Masuyama, N.,
Nishita, M.,
Fujisawa, J.,
Shibuya, H.,
Matsumoto, K.,
and Nishida, E.
(1999)
J. Biol. Chem.
274,
27161-27167
|
| 28.
|
Sano, Y.,
Harada, J.,
Tashiro, S.,
Gotoh-Mandeville, R.,
Maekawa, T.,
and Ishii, S.
(1999)
J. Biol. Chem.
274,
8949-8957
|
| 29.
|
Blanchette, F.,
Rudd, P.,
Grondin, F.,
Attisano, L.,
and Dubois, C. M.
(2001)
J. Cell Physiol.
188,
264-273
|
| 30.
|
Hoodless, P. A.,
Haerry, T.,
Abdollah, S.,
Stapleton, M.,
O'Connor, M. B.,
Attisano, L.,
and Wrana, J. L.
(1996)
Cell.
85,
489-500
|
| 31.
|
Albanese, C.,
Johnson, J.,
Watanabe, G.,
Eklund, N.,
Vu, D.,
Arnold, A.,
and Pestell, R. G.
(1995)
J. Biol. Chem.
270,
23589-23597
|
| 32.
|
Brunet, A.,
Pages, G.,
and Pouysségur, J.
(1994)
Oncogene
9,
3379-3387
|
| 33.
|
Pages, G.,
Lenormand, P.,
L'Allemain, G.,
Chambard, J. C.,
Meloche, S.,
and Pouyssegur, J.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
18,
8319-8323
|
| 34.
|
McKenzie, F. R.,
and Pouysségur, J.
(1996)
J. Biol. Chem.
271,
13476-13483
|
| 35.
|
Langlois, M. F.,
Zanger, K.,
Monden, T.,
Safer, J. D.,
Hollenberg, A. N.,
and Wondisford, F. E.
(1997)
J. Biol. Chem.
272,
24927-24933
|
| 36.
|
Aliaga, J. C.,
Deschenes, C.,
Beaulieu, J. F.,
Calvo, E. L.,
and Rivard, N.
(1999)
Am. J. Physiol.
277,
G631-G641
|
| 37.
|
Peterson, G. L.
(1977)
Anal. Biochem.
83,
346-356
|
| 38.
|
Brondello, J. M.,
McKenzie, F. R.,
Sun, H.,
Tonks, N. K.,
and Pouysségur, J.
(1995)
Oncogene.
10,
1895-1904
|
| 39.
|
Letterio, J. J.
(2000)
Cytokine Growth Factor Rev.
11,
81-87
|
| 40.
|
Lebman, D. A.,
and Edmiston, J. S.
(1999)
Microbes Infect.
1,
1297-1304
|
| 41.
|
Letterio, J. J.,
and Roberts, A. B.
(1998)
Annu. Rev. Immunol.
16,
137-161
|
| 42.
|
Sun, H.,
King, A. J.,
Diaz, H. B.,
and Marshall, M. S.
(2000)
Curr. Biol.
10,
281-284
|
| 43.
|
Favata, M. F.,
Horiuchi, K. Y.,
Manos, E. J.,
Daulerio, A. J.,
Stradley, D. A.,
Feeser, W. S.,
Van Dyk, D. E.,
Pitts, W.,
Earl, R. A.,
Hobbs, F.,
Copeland, R. A.,
Magolda, R. L.,
Scherle, P. A.,
and Trzaskos, J. M.
(1998)
J. Biol. Chem.
273,
18623-18632
|
| 44.
|
Liu, F.,
Hata, A.,
Baker, J. C.,
Doody, J.,
Carcamo, J.,
Harland, R. M.,
and Massagué, J.
(1996)
Nature.
381,
620-623
|
| 45.
|
Moustakas, A.,
and Kardassis, D.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
6733-6738
|
| 46.
|
de Caestecker, M. P.,
Parks, W. T.,
Frank, C. J.,
Castagnino, P.,
Bottaro, D. P.,
Roberts, A. B.,
and Lechleider, R. J.
(1998)
Gen. Dev.
12,
1587-1592
|
| 47.
|
Tsukazaki, T.,
Chiang, T. A.,
Davison, A. F.,
Attisano, L.,
and Wrana, J. L.
(1998)
Cell.
95,
779-791
|
| 48.
|
Hayashida, T.,
Poncelet, A. C.,
Hubchak, S. C.,
and Schnaper, H. W.
(1999)
Kidney Int.
56,
1710-1720
|
| 49.
|
Watanabe, H.,
de Caestecker, M. P.,
and Yamada, Y.
(2001)
J. Biol. Chem.
276,
14466-14473
|
| 50.
|
Yue, J.,
and Mulder, K. M.
(2000)
J. Biol. Chem.
275,
30765-30773
|
| 51.
|
Atfi, A.,
Djelloul, S.,
Chastre, E.,
Davis, R.,
and Gespach, C.
(1997)
J. Biol. Chem.
272,
1429-1432
|
| 52.
|
Yue, J.,
Buard, A.,
and Mulder, K. M.
(1998)
Oncogene
17,
47-55
|
| 53.
|
Yu, S. J.,
Boudreau, F.,
Désilets, A.,
Houde, M.,
Rivard, N.,
and Asselin, C.
(1999)
Biochem. Biophys. Res. Commun.
259,
544-549
|
| 54.
|
Santibanez, J. F.,
Iglesias, M.,
Frontelo, P.,
Martinez, J.,
and Quintanilla, M.
(2000)
Biochem. Biophys. Res. Commun.
273,
521-557
|
| 55.
|
Hartsough, M. T.,
and Mulder, K. M.
(1995)
J. Biol. Chem.
270,
7117-7124
|
| 56.
|
Han, J.,
Hajjar, D. P.,
Tauras, J. M.,
Feng, J.,
Gotto, A. M., Jr.,
and Nicholson, A. C.
(2000)
J. Biol. Chem.
275,
1241-1246
|
| 57.
|
Soma, Y.,
and Grotendorst, G. R.
(1989)
J. Cell. Physiol.
140,
246-253
|
| 58.
|
Leof, E. B.,
Proper, J. A.,
Goustin, A. S.,
Shipley, G. D.,
DiCorleto, P. E.,
and Moses, H. L.
(1986)
Proc. Natl. Acad. Sci. U. S. A.
83,
2453-2457
|
| 59.
|
Kretzschmar, M.,
Doody, J.,
Timokhina, I.,
and Massagué, J.
(1999)
Genes Dev.
13,
804-816
|
| 60.
|
Xiao, Z.,
Liu, X.,
and Lodish, H. F.
(2000)
J. Biol. Chem.
275,
23425-23428
|
| 61.
|
Hubner, S.,
Xiao, C. Y.,
and Jans, D. A.
(1997)
J. Biol. Chem.
272,
17191-17195
|
| 62.
|
Chrétien, M.,
Mbikay, M.,
Gaspar, L.,
and Seidah, N. G.
(1995)
Proc. Assoc. Am. Physicians
107,
47-66
|
| 63.
|
Hoshino, H.,
Konda, Y.,
and Takeuchi, T.
(1997)
FEBS Lett.
419,
9-12
|
| 64.
|
Kayo, T.,
Konda, Y.,
Tanaka, S.,
Takata, K.,
Koizumi, A.,
and Takeuchi, T.
(1996)
Endocrinology
137,
5126-5134
|
| 65.
|
Seidah, N. G.,
and Chretien, M.
(1999)
Brain Res.
848,
45-62
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. Thompson, S. McMahon, Y. Bosse, C. M. Dubois, J. Stankova, and M. Rola-Pleszczynski
Leukotriene D4 Up-Regulates Furin Expression through CysLT1 Receptor Signaling
Am. J. Respir. Cell Mol. Biol.,
August 1, 2008;
39(2):
227 - 234.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R.-N. Chen, Y.-H. Huang, Y.-C. Lin, C.-T. Yeh, Y. Liang, S.-L. Chen, and K.-H. Lin
Thyroid Hormone Promotes Cell Invasion through Activation of Furin Expression in Human Hepatoma Cell Lines
Endocrinology,
August 1, 2008;
149(8):
3817 - 3831.
[Abstract]
[Full Text]
[PDF]
|
 |
|